Novavax, Inc. (NVAX)
$7.67
Rating:
Recommendation:
Neutral
Symbol | NVAX |
---|---|
Price | $7.67 |
Beta | 1.683 |
Volume Avg. | 9.18M |
Market Cap | 773.934M |
Shares () | - |
52 Week Range | 5.61-25.66 |
1y Target Est | - |
DCF Unlevered | NVAX DCF -> | |
---|---|---|
DCF Levered | NVAX LDCF -> | |
ROE | 82.35% | Strong Buy |
ROA | -34.82% | Strong Sell |
Operating Margin | - | |
Debt / Equity | -26.37% | Neutral |
P/E | -1.08 | Sell |
P/B | -0.91 |
Latest NVAX news
About
Download (Excel)Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.